Adropin deficiency worsens HFD-induced metabolic defects

Shi Chen1,11, Kai Zeng2,11, Qi-cai Liu3,3, Zheng Guo4, Sheng Zhang5, Xiao-rong Chen6, Jian-hua Lin7, Jun-ping Wen8, Cheng-fei Zhao9, Xin-hua Lin10 and Feng Gao*,5

The limited efficacy of current treatment methods and increased type 2 diabetes mellitus (T2DM) incidence constitute an incentive for investigating how metabolic homeostasis is maintained, to improve treatment efficacy and identify novel treatment methods. We analyzed a three-generation family of Chinese origin with the common feature of T2DM attacks and fatty pancreas (FP), alongside 19 unrelated patients with FP and 58 cases with T2DM for genetic variations in Enho, serum adropin, and relative Treg amounts. Functional studies with adropin knockout (AdrKO) in C57BL/6J mice were also performed. It showed serum adropin levels were significantly lower in FP and T2DM patients than in healthy subjects; relative Treg amounts were also significantly decreased in FP and T2DM patients, and positively associated with adropin (r = 0.7220, P = 0.0001). Sequencing revealed that the patients shared a Cys66Trp mutation in Enho. In vivo, adropin-deficiency was associated with increased severity of glucose homeostasis impairment and fat metabolism disorder. AdrKO mice exhibited reduced endothelial nitric oxide synthase (eNOS) phosphorylation (Ser1177), impaired glycosphingolipid biosynthesis, adipocytes infiltrating, and loss of Treg, and developed FP and T2DM. Adropin-deficiency contributed to loss of Treg and the development of FP disease and T2DM.

Cell Death and Disease (2017) 8, e3008; doi:10.1038/cddis.2017.362; published online 24 August 2017

Obesity arises from a sustained positive energy balance that triggers a pro-inflammatory response, a key contributor to metabolic diseases such as T2DM (type 2 diabetes mellitus) and pancreatic steatosis.1 Specific metabolites can modulate the functional nature and inflammatory phenotype of immune cells. In obesity, the expanding adipose tissue attracts immune cells, creating an inflammatory environment within this fatty acid storage organ.2 Inflammatory mediators, such as TNF-α and IL-1, are induced by saturated fatty acids, and disrupt insulin signaling and metabolic switch in their function. Ectopic fat can also affect pancreatic β-cell function, thereby contributing to insulin resistance.3–5

In the obese state, the storage capacity of adipose tissue is exceeded. Free fatty acids (FFAs) ‘spill over’ and accumulate in metabolic tissues such as the skeletal muscle, liver, and pancreas, causing lipotoxicity. Excess FFAs in turn activate inflammatory pathways and impair normal cell signaling within immune cells and adipose tissue, as well as the liver and muscle, causing cellular dysfunction.6 Consequently, metabolic disorders such as insulin resistance and type 2 diabetes can develop. Similar to the liver and skeletal muscle, the pancreas is a metabolic organ negatively impacted by obesity-induced lipotoxicity and glucotoxicity.7 Indeed, obesity-associated insulin resistance increases the metabolic demand on β-cells.8 Eventually, these cells are unable to continue the compensatory mechanism; hyperglycemia ensues, driven by the elevated FFA levels. The combined deleterious effects of glucotoxicity and lipotoxicity, referred to as glucolipotoxicity, eventually causes β-cell failure characteristic of T2DM.9 Chronic hyperglycemia as found in obesity-induced insulin resistance promotes the development of glucotoxicity.10 Several peptide hormones secreted by the endocrine pancreas, gut, adipocytes, and liver modulate insulin activity to maintain glucose homeostasis and fat amounts; these hormones are considered promising leads in the development of therapies against T2DM and fatty liver or pancreas disease.11,12

Adropin is a peptide hormone that was originally described as a secreted peptide, with residues 1-33 encoding a secretory signal peptide sequence. It plays a role in energy homeostasis as well as glucose and fatty acid metabolism. This protein is encoded by the Enho (Energy Homeostasis Associated) gene, which is expressed primarily in the liver, pancreas, and central nervous system. How adropin secretion is secreter remains controversial. It was shown that adropin is mainly regulated by miRNAs, along with the only gene

1Department of Hepatobiliary Surgery, Fujian Provincial Hospital, Fujian Medical University, Fuzhou, China; 2Department of Anesthesiology, 1st Affiliated Hospital, Fujian Medical University, Fuzhou, China; 3Department of Laboratory Medicine, 1st Affiliated Hospital, Fujian Medical University, Fuzhou, China; 4Department of Bioinformatics, Fujian Medical University, Fuzhou, China; 5Department of Pathology, 1st Affiliated Hospital, Fujian Medical University, Fuzhou, China; 6Department of Radiology, 1st Affiliated Hospital, Fujian Medical University, Fuzhou, China; 7Department of Central Laboratory, 1st Affiliated Hospital, Fuzhou, China; 8Department of Endocrinology, Fujian Provincial Hospital, Fuzhou, China; 9Department of Pharmaceutical Analysis, Fujian University, Putian, China; 10Department of Pharmaceutical Analysis, Fujian Medical University, Fuzhou, China
*Corresponding author: O-c Liu, Department of Laboratory Medicine, 1st Affiliated Hospital, Fujian Medical University, 20 Chazhong Road, Fuzhou 350005, China. Tel/Fax: +86 591 879 819 72; E-mail: lqc673673673@163.com
or F gao, Department of Pathology, 1st Affiliated Hospital, Fujian Medical University, 20 Chazhong Road, Fuzhou 350005, China. Tel/Fax: +86 591 879 819 68; E-mail: fengfang77777@163.com
11These authors contributed equally to this work.
Received 27.5.17; revised 22.6.17; accepted 23.6.17; Edited by H-U Simon
Adropin deficiency worsens HFD-induced metabolic defects

S Chen et al
responsible for nonshivering thermogenesis (mitochondrial uncoupling protein 1, or UCP1) in brown adipose tissue. Moreover, adropin-deficiency exhibits loss of T\textsubscript{reg} and results in autoimmune diseases. T\textsubscript{reg} are involved in controlling the inflammatory state of adipose tissue, and thus insulin sensitivity. Although visceral adipose tissue invasion by proinflammatory macrophages is considered a key event driving adipose-tissue inflammation and insulin resistance, little is known about the roles of T\textsubscript{reg} in these processes and the driver of T\textsubscript{reg}. Expectedly, in vivo, T\textsubscript{reg} responses are necessary for complete restoration of insulin sensitivity and dyslipidemia. Adropin is involved in the mechanism of increased adiposity, insulin resistance, and glucose and lipid metabolism. More interestingly, we found that almost all patients with pancreatic steatosis were diagnosed with diabetes; in addition, En\textsubscript{rho} mutations were found in a three-generation family of Chinese origin with the common feature of T2DM attacks and FP. Therefore, adropin may play a role in the pathogeneses of FP and T2DM.

**Results**

**Clinical characteristics.** A 53-year-old female (the proband, III6) (Figure 1a) presented with chief complaints of foul smelling stools, with a high frequency of 3–4 times a day for the last 10 years. Stools were copious in amount and difficult to flush, floating in the pan. She was hospitalized at the age of 10 years, and diagnosed with pancreatic insufficiency; diabetes was diagnosed when she was 23. Pancreatic enzyme supplements were started, and her diarrhea improved. There was no history of jaundice/pruritus/pale stool/osmotic symptoms or any signs suggestive of pancreatitis/pancreatic cancer. Computed tomography (CT) of the

---

**Figure 1** Identification of En\textsubscript{rho} mutations in fatty pancreas and diabetes. (a) The pedigree of the family affected by fatty pancreas and diabetes, fatty pancreas patients (■●), type II diabetes mellitus patients (□●), and their family normal members (○□). (b) Computed tomography (CT) revealed total homogenous replacement of the pancreas by fat (top), fat-suppression showed pancreatic signal reduction and decreased pancreatic parenchyma (bottom). (c) MRI T2WI and T1WI showed fatty tissues were seen within the region of the pancreas from the proband (III6). Left top: T1WI, Left bottom: T1WI fat-suppression (enhanced), Right top: T1WI fat-suppression, Right bottom: T2WI fat-suppression. (d) Patient III7, the sister of the proband: CT and CT enhanced scan showed pancreas morphology remained visible and pancreatic duct resulted in a fishbone like change, normal pancreatic tissue was substituted by adipose tissue. (e) p.Cys56T\textsubscript{rp}, p.Tyr72T\textsubscript{yr}, and c."238T>C mutations which were validated by Sanger sequencing. (f) The medium levels of serum adipoplin before therapy in the patients with fatty pancreas and diabetes and that of the healthy subjects. (g) Serum adipoplin inversely associated with glucose. (h) Serum adipoplin inversely associated with HbA1c. (i) Pancreatic steatosis is histologically characterized by an increased number of adipocytes or expansion of existing adipocyte size (III7). (j) Fibrosis and fat in intralobular locations in the pancreatic tissue (III6)
abdomen revealed total homogenous replacement of the pancreas by fat (Figure 1b). MRI T2WI and T1WI showed fatty tissue within the region of the pancreas. There was almost no normal pancreatic parenchyma, and the area was completely filled with adipose tissue (Figure 1c).

Because most of her family members suffered from diabetes or/and fatty pancreas (FP), a detailed investigation was carried out to further assess the relationship between FP and diabetes. Family history was notable for the appearance of similar symptoms in multiple members of this family across three generations, with the common feature of diabetes attacks. The pedigree of this family contained 32 members, including 18 subjects with diabetes or FP phenotype and 14 without phenotype (Figure 1a). The family members with diabetes had a similar age of onset (20–32 years old). Patient III7, the proband’s sister, a 60-year-old female, suffered from pancreatic insufficiency at the age of 16, and was diagnosed with diabetes at 30 years old. CT and enhanced CT scan showed the pancreatic duct had a fishbone like change, with normal pancreatic tissue substituted by adipose tissue (Figure 1d).

Loss of adropin and Treg in patients with FP and T2DM. Medium levels of serum adropin before therapy were significantly lower in patients with FP than in healthy subjects (n=22; 244.50 pg/ml (89.00–523.00 pg/ml) and n=72, 336.88 pg/ml (136.20–811.75 pg/ml), respectively; P=0.0205). In addition, lower levels were also found in patients with T2DM compared with the normal control group (n=58, 178.13 pg/ml; 7.15–569.20 pg/ml, P<0.0001) (Figure 1f). Moreover, serum adropin levels were lower in the T2DM group than FP patients (P=0.0119, T2DM versus FP). More excitingly, serum adropin

**Figure 2** Loss of adropin and Treg cells in the patients with FP and T2DM. (a) The relative numbers of Treg cells were significantly decreased in patients with FP and T2DM. (b) The relative numbers of Treg cells were positively associated with adropin. (c) The relative numbers of Treg cells were inversely associated with HbA1c. (d) The relative numbers of Treg cells was not relative to total cholesterol (TC). (e) The relative numbers of Treg cells was not relative to total glyceride (TG). (f) The relative numbers of Treg cells was not relative to free fatty acids (FFA).
was inversely associated with glucose \((r = -0.5942, P = 0.0035)\) (Figure 1g) and HbA1c \((r = -0.7834, P < 0.0001)\) (Figure 1h).

Unlike non-alcoholic fatty liver disease, where triglyceride accumulation is mainly intracellular, pancreatic steatosis is histologically characterized by an increased number of adipocytes, a size expansion of existing adipocytes (Figure 1i), fibrosis and fat in intra-lobular locations (Figure 1j). Interestingly, almost all patients with FP were diagnosed with T2DM.

Furthermore, relative T_{reg} amounts were significantly decreased in patients with FP and T2DM (\(P < 0.0001\), \(P < 0.0001\), versus normal control) (Figure 2a), positively associated with adropin levels \((r = 0.7220, P = 0.0001)\) (Figure 2b), and inversely associated with hemoglobin A1C \((HbA1c) \(r = -0.6082, P = 0.0027)\) (Figure 2c). Surprisingly, T_{reg} amounts were not correlated with total cholesterol \((r = 0.02825, P = 0.9007)\) (Figure 2d), total glyceride (TG)
Pathogenesis of fatty pancreas disease and diabetes in AdrKO mice. To explore the possibility that adropin serves as an endogenous protective substance for the pancreas, AdrKO mice (Figure 3a) were used to assess the effect of adropin-deficiency on the formation of FP disease and/or diabetes. F5 intercrossed mice were genotyped by Sanger sequencing. Hematoxylin and eosin (H&E) staining of biopsy specimens from AdrKO mice revealed typical histopathological features, including a high number of adipocytes infiltrating the exocrine pancreas (Figure 3b), which is common in human FP disease. We further analyzed glucose levels, which were significantly higher in AdrKO mice (n=12, 8.33±1.36 mmol/l, 6.90–13.20 mmol/l) compared with the values of WT mice (n=7, 5.80±0.85 mmol/l, 4.40–8.20 mmol/l, P<0.0001) (Figure 3c), at 12 months with normal diet. Interestingly, 4 of 12 AdrKO mice developed diabetes (non-fasting blood glucose levels ≥300 mg/dl). We next explored whether adropin-deficiency is associated with insulin resistance in AdrHET mice. Our results showed that adropin levels were inversely associated with insulin (INS) (r=-0.3945, P=0.0693, n=22) (Figure 3d), as also reflected by INS immunohistochemistry, which showed apparently increased islet size in AdrKO mice compared with WT mice (Figure 3e).

AdrKO mice exhibited reduced eNOS phosphorylation: immunohistochemical staining showed that eNOS phosphorylation at Ser1177 was significantly lower in tissues from AdrKO mice than those of negative control littermates, which was reflected as such in the brain (neuronal cells), kidney (perivascular), and pancreas (perivascular) (Figure 3e).

Adropin-deficiency is associated with increased severity of obesity-related impaired glucose homeostasis. Body weights were not significantly different between the WT, HET and KO groups by pairwise comparison after 8 weeks weaning onto chow (Figure 4a). After 8 weeks on high-fat diet (60% kJ/fat, HFD) (n=6/group), body weights of heterozygous carriers of the null adropin allele (HET) and adropin knockout (KO) mice were significantly higher than those of wild-type (WT) controls (P=0.0417, P=0.0018, respectively); however, there were no significant differences between the HET and KO groups (P=0.1358). Serum insulin levels in HET and KO groups were significantly higher than WT values (P=0.0015, P<0.0001, respectively) at the end of 8 weeks on HFD (Figure 4b). Moreover, AdrKO mice exhibited fasting hypertriglyceridemia (P<0.0001 versus WT), but AdrHET mice showed no significant difference (P=0.6867 versus WT) (Figure 4c). The OGTT showed 60-min (Figures 4d and e) and 120-min (Figures 4d and f) glucose levels were significantly higher than WT levels recorded at 8 weeks on HFD. Hyperinsulinemia and hyperglycemia were more severe in adropin knockout mice than in AdrHET mice. Almost all AdrKO mice developed fasting hyperglycemia at 30 weeks (Figure 4g). Glucose intolerance defined: Fasting plasma glucose is higher than the average value add 3 standard deviation of normal mice, that is fasting plasma glucose >13.9 mmol/l. In one word, impaired glucose tolerance associated with diet-induced obesity was more severe in heterozygous and homozygous carriers of the null adropin allele.
Expression profiling of pancreatic tissue isolates by RNA-SEQ. We observed a strong transcriptional interferon response gene signature, and decreased levels of adropin and other interferon-induced cytokines, in pancreatic tissues. A total of 973 putative differentially expressed genes were selected with a cut-off p-value of 0.05 and fold change of 1.5 (three biological replicates; Figure 5a). As predicted, most downregulated genes were associated with peroxisome proliferator-activated receptor (PPAR) and adipocytokine signaling pathways; accordingly, Ingenuity pathway analysis (IPA) predicted the top upstream regulator to be organism death (p-value: 0.00528, Activation z-score: -4.695, Molecules: 77) (Table 1). However, many functions associated with steroidogenesis (downregulation), lipid metabolism (downregulation), and apoptosis (increased) also scored high. Notable upregulated genes included IL1, IL33, and TNFR. The other upregulated genes were mainly observed in AdrKO mice, for example, transcription factor AP-2 epsilon (Tafp2e), heat shock protein 3 (Hspb3), and olfactory receptor 267 (Olftr267). Downregulated genes were mainly enriched in the functions of glycosphingolipid biosynthesis and blood circulation, for example, glucose-6-phosphate dehydrogenase 2 (G6pd2), cAMP responsive element binding protein 3-like 3 (Creb3l3), 5-hydroxytryptamine (serotonin) receptor 1D (Htr1d), and UDP-Gal: beta-GlcNAc beta 1,3-galactosyltransferase, polypeptide 5 (B3galt5). GOSim and SubpathwayMiner were employed for enrichment analysis of coding genes from each specific cluster based on GO terms and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways. Each cluster was annotated with the enriched functions of the corresponding gene set, such as glycolysis/gluconeogenesis, adipocytokine signaling pathway, and PPAR signaling pathway (Figure 5b) which improves glycemic control, lipid metabolism, and insulin sensitivity in type 2 diabetes.

Canonical pathway enrichment during adropin deficiency. To determine which pathways were activated during adropin deficiency and potential differences between T2DM and FP, we performed a canonical pathway enrichment analysis using IPA, which showed organisal injury and abnormalities, gastrointestinal disease, and hereditary disorder as the most significantly enriched pathways, as such functions are necessary for gastrointestinal-pancreatic-immunology, confirming the role of adropin deficiency in DM and FP (Supplementary Figure 1). To determine regulatory networks involving significantly up- or downregulated mRNAs in each category, all significant mRNAs (FC >1.5) in each exposure and pathology category were analyzed using an IPA target filter. Adropin deficiency mainly activated the platelet-derived growth factor (PDGF), IL-1, and TNF pathways, and inhibited RXR complex (PPAR-RXR) formation, thereby inhibiting glucose uptake, adipocyte differentiation, and macrophage function (Figure 5c).

Adropin-deficiency through the TNF-α/NF-κB pathway inhibits PPAR-RXR complex formation and glycolipid metabolism. Meanwhile, pro-inflammatory factors, such as IL-1β, TNF-α and PDGF, induce cell apoptosis, autophagy, and inhibit PARRG activity. As discussed below, the anti-inflammatory feature of adropin-deficiency seems to positively contribute to mitigate this stress-related inflammatory response. To validate the pathways predicted by RNA-SEQ and IPA, we performed immunohistochemical analysis of pancreatic tissue specimens from a patient (II6) as well as AdrKO and AdrHet mice. Our results showed that serum TNF-α levels were inversely associated with adropin ($R^2 = -0.2050$, $P = 0.0343$, $n = 22$) in AdrHet mice (Figure 6b), while TNF-α levels were higher in AdrKO mice than in the WT counterparts ($P < 0.0001$, $n = 3$) (Figure 6c); this was also reflected by immunohistochemistry, which showed that TNF-α appeared to be expressed around adipose tissue in the pancreas specimens from FP patients (Figure 6a). The pro-inflammatory transcription factor nuclear factor kappa B (NF-κB) is a key regulator of inflammation, while the transcription factor peroxisome proliferator-activated receptor gamma (PPARγ) is a key modulator of genes involved in diabetes development. In this study, NF-κB was strongly expressed around nerve fibers (Figure 6d), small blood vessels and adipose tissue (Figure 6e) in patient II6. PPARγ levels were significantly lower in pancreas samples from AdrKO mice compared with normal controls (Figure 6f).

Adropin deficiency causes reduced eNOS phosphorylation and loss of Treg. Adropin enhances the expression of eNOS in the endothelium via activation of vascular endothelial growth factor receptor 2 (VEGFR2) pathways. Thus, we assessed the co-localization of CD31 (endothelium cell marker), eNOS, adropin, and VEGFR2 in endothelial layers. We found that adropin and p-eNOS levels in pancreatic tissues from AdrKO mice were lower than those obtained for WT mice (Figures 7a and b). For the sub-cellular localization of proteins, tissue immunofluorescence for staining in endothelial layers showed that CD31 and eNOS overlap (yellow staining in the merged image) was also lower in AdrKO mice (Figure 7b), indicating that adropin-deficiency reduced p-eNOS.

Meanwhile, the proportions and absolute amounts of CD4+ Foxp3+ (Treg) cells were significantly decreased in myocardial (Figure 7c) and pancreatic tissues (Figure 7d) from AdrKO mice compared with the matched Enho+/- littermates, which further suggested that adropin-deficiency was associated with the inhibition of Treg. The majority of Treg were distributed only around the pancreatic duct or blood vessels in tissues from AdrKO animals (Figure 7c), and scattered in wild-type specimens (Figure 7d).

Discussion

Adropin, a recently described peptide hormone produced in the brain, liver, and pancreas, has been reported to have physiologically relevant actions on glucose homeostasis and lipogenesis, exerting significant effects on endothelial function. It is encoded by the Energy Homeostasis Associated gene (Enho), whose expression is influenced by fasting. However, chronic exposure to high-fat diet is associated with reduced expression of adropin. In the current study, AdrKO mice were sensitive to obesity when fed HFD but not chow. With time, almost all AdrKO mice developed diabetes under high-fat induction. Furthermore, there was a significant
**Figure 5** Expression profiling of pancreatic tissue isolates by RNA-SEQ. (a) The heatmap depicts hierarchical clustering based on the 973 differentially expressed genes. Unsupervised hierarchical clustering was done with complete linkage. Heatmap visualization for the pancreatic tissues of AdrKO mice and WT mice ($n = 3$). Rows: samples; Columns: metabolites; Color key indicates metabolite expression value, blue: lowest; red: highest. (b) Importantly KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway mapping of the entire set of differentially expressed genes revealed highly significant molecular interactions for KEGG entries Glycosphingolipid biosynthesis-lacto and neolacto series, Ubiquinone and other terpenoid-quinone biosynthesis. X-axis is an inverse indication of $P$-value or significance. (c) IPA signaling pathway analysis of potential intervention targets of adropin-deficiency. Ingenuity analysis of top pathways affected in differentially expressed genes between AdrKO and controls, mRNAs (FDR 10%, FC $>1.5$). Red symbols specify upregulated expression of genes, whereas green symbols indicate downregulated genes. The color darkness represents the FC intensity. 

Adropin deficiency worsens HFD-induced metabolic defects

S Chen et al

Cell Death and Disease
Elevated blood levels of glucose and insulin were detected in AdrKO and AdrHET mice. Furthermore, this study described the RNA-seq profiles of pancreatic tissues from AdrKO mice; there were 86 genes identified as involved in glycosphingolipid or ubiquinone biosynthesis, adipocytokine signaling pathway, PPAR signaling pathway, and the biosynthesis of other terpenoid-quinones. PPARs are lipid-activated transcription factors; their characterized target genes encode proteins that participate in lipid homeostasis. In this study, RXRs had lower expression levels in AdrKO mice; meanwhile, coordination and cross-talk among multiple components of this network are critical to ensure correct energy balance and insulin resistance. Other examples are N-acetyltransferase, glucose-6-phosphate dehydrogenase (G6PD), transcription factor AP-2, and heat shock protein, which contribute to susceptibility to type 2 diabetes and FP disease by inhibiting glucose-induced insulin secretion in pancreatic β cells or naringen attenuated insulin resistance; adropin deficiency downregulated peNOS whose uncoupling contributes to endothelial dysfunction. To further explore the signal transduction pathways involved in adropin-attenuated impaired angiogenesis in diabetic mice, we examined the effects of adropin on eNOS phosphorylation in AdrKO mice, which showed reduced eNOS (Ser1177) phosphorylation within perivascular cells from the kidney and pancreas, as well as neuronal cells.

Adropin-deficiency worsens HFD-induced metabolic defects
S Chen et al

| Function annotation                                      | P-value | Activation z-score | Molecules |
|----------------------------------------------------------|---------|--------------------|-----------|
| Lymphoid cancer and tumors                               | 1.57E-03| -2.246             | 100       |
| Lymphohematopoietic neoplasia                            | 1.39E-03| -2.274             | 105       |
| Hematological neoplasia                                  | 1.78E-03| -2.595             | 104       |
| Lymphoproliferative malignancy                           | 1.89E-03| -2.944             | 87        |
| Lymphoma cancer                                           | 2.10E-03| -2.578             | 98        |
| Lymphohematopoietic cancer                               | 3.28E-03| -2.595             | 101       |
| Hematologic cancer                                        | 4.04E-03| -2.941             | 100       |
| Abdominal neoplasm                                       | 9.26E-10| -2.143             | 304       |
| Gonadogenesis                                             | 1.42E-03| 2.289              | 23        |
| Gametogenesis                                             | 4.76E-04| 2.254              | 21        |
| Hypoplasia of lymphoid organ                             | 1.04E-02| -2.216             | 8         |
| Agensis                                                  | 3.39E-03| -2.138             | 8         |
| DNA replication                                           | 2.59E-03| 2.415              | 12        |
| Radiosensitivity of cells                                | 8.85E-05| -2.236             | 5         |
| Incidence of lymphoma                                    | 1.41E-02| -2.428             | 6         |
| Differentiation of blood cells                           | 9.83E-03| 2.049              | 30        |
| Spermatogenesis                                          | 4.45E-04| 2.066              | 19        |
| Development of genital organ                             | 1.47E-03| 2.289              | 24        |
| Organismal death                                         | 5.28E-03| -4.695             | 77        |

Table 1 Disease and Functions
Figure 6  Adropin deficiency through TNF-α/NF-κB pathway to inhibited PPARγ. (a) TNF-α appears to be expressed around the nerve fiber in the pancreas from the FP patients (II7), the black arrow refers to adipose cells. (b) Serum TNF-α levels were inversely associated with adropin ($R^2 = -0.2050$, $P = 0.0343$, $n = 22$) in AdrHET mice. (c) Serum TNF-α was higher in the AdrKO mice than that of WT mice ($P < 0.0001$, $n = 3$). (d) NF-κB was strongly expressed around the small blood vessels and adipose tissue in patient II7, the black arrow refers to adipose cells. (e) NF-κB was strongly expressed around the nerve fiber; the black arrow refers to adipose cells. (f) PPARγ levels were significantly lower in pancreas from AdrKO mice compared to healthy controls.
the reason for most FP patients having normal blood lipid levels.\textsuperscript{33-35}

The effects of pancreatic fat on insulin resistance and beta-cell function have been investigated in animal and human studies.\textsuperscript{36,37} However, it remains unclear whether FP disease and type 2 diabetes share common mechanisms. In this study, we demonstrated that diabetes and pancreatic fat disease mainly result from genetic susceptibility and diet interactions.

|   | DAPI | Adropin | VEGFR2 | Merger |
|---|------|---------|--------|--------|
| KO | ![Image](ko_dapi.png) | ![Image](ko_adropin.png) | ![Image](ko_vegfr2.png) | ![Image](ko_merger.png) |
| WT | ![Image](wt_dapi.png) | ![Image](wt_adropin.png) | ![Image](wt_vegfr2.png) | ![Image](wt_merger.png) |

|   | DAPI | PeNOS | CD31 | Merger |
|---|------|-------|------|--------|
| KO | ![Image](ko_dapi.png) | ![Image](ko_peenos.png) | ![Image](ko_cd31.png) | ![Image](ko_merger.png) |
| WT | ![Image](wt_dapi.png) | ![Image](wt_peenos.png) | ![Image](wt_cd31.png) | ![Image](wt_merger.png) |

|   | DAPI | Foxp3 | CD4 | Merger |
|---|------|-------|-----|--------|
| KO | ![Image](ko_dapi.png) | ![Image](ko_foxp3.png) | ![Image](ko_cd4.png) | ![Image](ko_merger.png) |
| WT | ![Image](wt_dapi.png) | ![Image](wt_foxp3.png) | ![Image](wt_cd4.png) | ![Image](wt_merger.png) |

**Figure 7**  Adropin-deficiency results in loss of p-eNOS and $T_{reg}$ cells. (a) Confocal immunofluorescence analysis showing diminutive areas of colocalized DNA in blue, adropin in green and VEGFR2 in red, the overlap of adropin and VEGFR2 (yellow staining in the merged image). (b) Confocal immunofluorescence analysis showing small areas of colocalized DNA in blue, CD31 in red and p-eNOS in green, overlap of CD31 and p-eNOS (yellow staining in the merged image) in the endothelial layers. (c) Colocalization of DNA (blue), CD4 (red) and Foxp3 (green) indicates $T_{reg}$ cells formation in myocardial. (d) Colocalization of DNA (blue), CD4 (red) and Foxp3 (green) indicates $T_{reg}$ cells formation in pancreatic tissues. Original magnification: x 400
A thorough understanding of adropin’s actions would advocate for the use of this protein for therapeutic purposes in diabetes and/or FP disease. We deduce that Enho mutations as well as lifelong sugar carbohydrate and fat-induced adropin deficiency may provide additional damage to the pancreas in fat accumulation and T2DM, by altering the number or function of Treg and stimulating autophagy.

Materials and Methods

Study population. A three-generation family of Chinese origin with the common feature of diabetes attacks (Figure 1a) included three patients with FP, 18 T2DM cases, and 13 normal controls. Additional 19 unrelated patients with FP and 58 T2DM cases were included; 220 population-matched healthy individuals served as controls. FP was diagnosed with increased echogenicity of the pancreatic body over that of the kidney based on the pathological diagnosis. This study was approved by the Ethics Committee of Fujian Medical University.

Analysis of Enho mutations, adropin, and the relative Treg cells number. Blood was collected and DNA extracted using a Tiangen Genomic extraction kit (Beijing, China). Full-length Enho was amplified, purified, and sequenced. Serum levels of adropin from the patients with FP or T2DM and normal controls were measured using a specific enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN, USA). We quantitated the relative Treg controls were measured using a specific enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN, USA). We quantitated the relative Treg number.

Gene targeting in AdrKO mice. AdrKO mice were generated by clustering regularly interspersed short palindromic repeats (CRISPR)-Cas9 by the Shanghai Biomodel Organism Science & Technology Development Co., Ltd., in the C57BL/6J background (Figure 2a). AdrKO, AdrHET, and wild-type (WT) mice were housed under a 12 h:12 h light-dark cycle at constant temperature (23 ± 1 °C) with free access to water. The animals were maintained on chow diet (Chow; 60% KJ provided by carbohydrates; 25% KJ/protein, and 14% KJ/fat) or HFD (60% KJ/fat, 20% KJ/carbohydrate, and 20% KJ/protein).

Glucose, insulin, and serum lipid measurements. For the GTT, mice were fasted overnight and injected c-glucose (1–2 g/kg body weight). Blood samples were obtained at various time points (0, 60 min, and 120 min) from the various types of mice (AdrKO, AdrHET, and WT), by tail-vein nick. Insulin levels in plasma were measured using an ELISA kit (Crystal Chem, Downers Grove, IL, USA). Serum lipids (triglycerides, cholesterol, and HDL) were measured by IDEXX Laboratories (West Sacramento, CA, USA).

Histology and immunohistochemistry. Pancreas tissue were fixed in 4% formalin overnight, embedded in paraffin, sectioned at 4 mm and stained with H&E for pathology. The following antibodies were used: anti-Insulin (AbCional), anti-\textit{p}-\textit{e}-NOS (Ser1177) (Santa Cruz, Santa Cruz, CA, USA).

RNA-seq and pathway mapping analysis. Assignment of metabolites was identified based on the published literature and databases such as HMDB, KEGG, PubChem compound database and SMPDB.13 Subsequent pathway mapping analysis was conducted with the IPA metabolomics model (http://www.ingenuity.com/products/pathways_analysis.html).

Localization of VEGFR2/adropin, CD31/p-eNOS and CD4/FoxP3. Immunofluorescence confocal microscopy was also undertaken to determine the correlation of VEGFR2 and adropin. VEGFR2 was detected with rabbit anti-human antibody (Sangon, Shanghai, China) and labeled with a goat anti-rabbit secondary antibody conjugated to Cy3. p-eNOS was detected with a mouse anti-human antibody (Santa, Santa Cruz, CA, USA) and labeled with a goat anti-mouse secondary antibody conjugated to FITC. Nuclear were stained using DAPI.

Treg was identified by staining using antiCD4 and antiFoxP3. CD4 was detected with a rabbit antihuman antibody (Sanying, Wuhan, China) and labeled with a goat anti-rabbit secondary antibody conjugated to Cy3. FoxP3 was detected with a mouse anti-human antibody (Santa, USA) and labeled with a goat anti-mouse secondary antibody conjugated to FITC. Nuclei were stained using DAPI.

Statistics. Statistical differences between groups were assessed by the nonparametric Mann–Whitney U-test for two groups and Kruskal–Wallis test for more than two groups. Bonferroni–Dunn’s correction method was applied for post hoc multiple pair-wise comparisons. Spearman’s rank correlation coefficient estimated the degree of association between two variables. Significance was calculated at P < 0.05 by GraphPad Prism 5 (La Jolla, CA, USA).

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (no. 81571613, no. 81572442, no. 81502008, and no. 81670264) and by the National key Technology R&D Program of China (no. 2012AA022804) and by Joint Fund for Program of Science innovation of Fujian Province, China (no. 2016Y9011). These funding sources played key supportive role for sample collection, molecular analysis of patient samples, bioinformatics analysis.

Author contributions

Q-CL, FG, and SC planned the project. KZ, Q-CL, FG, J-PW, and SG conceived of and designed the study. FG, J-HL, X-LC, C-FZ, and ZG performed the sample collection. SC, FG, and ZG performed immunohistochemistry. Q-CL, FG, and SC participated in the in vivo procedures. Q-CL, FG, and S.Z performed the expression analysis. O.-CL, FG., X.-HL., and K.Z. analyzed the data and drafted the manuscript. All authors reviewed the manuscript and approved the final version.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

1. Smits MM, van Geenen EJ. The clinical significance of pancreatic steatosis. Nat Rev Gastroenterol Hepatol 2011; 8: 169–177.
2. Ciclitella D, Feurer M, L A, Kame N, Lee J, Shoelson SE et al. PPARγ is a major driver of the accumulation and phenotype of adipose-tissue Treg cells. Nature 2012; 486: 549–553.
3. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Kain M et al. Reversal of obesity and diet-induced insulin resistance with salicylates or targeted disruption of IkBkota. Science 2001; 293: 1673–1677.
4. Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: unravelling the mechanism. Lancet 2010; 375: 2267–2277.
5. Hotamisligil GS, Shargil NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87–91.
6. Krahmer N Jr, Farese RV, Walther TC. Balancing the fat: lipid droplets and human disease. Endo Mol Med 2012; 5: 973–983.
7. Benessam M, Laybutt DR, Jonas JC. The molecular mechanisms of pancreatic \textit{p}-\textit{e}-glucocytotaxy: recent findings and future research directions. Mol Cell Endocrinol 2012; 364: 1–27.
8. Fex M, Nitrer MD, Wiais R, Sullider C, Milc R. Enhanced mitochondrial mechanism. Diabetes 2013; 4: 74–83.
9. Robertson RP, Harmon J, Tran PO, Tanaka Y, Takahashi H. Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 2003; 52: 581–587.
10. Beach T. Pancreas: fatty pancreas linked to increased BMI and insulin resistance in children. Nat Rev Gastroenterol Hepatol 2015; 12: 489.
11. Barrera JG, Sandoval DA, D’ Alessio DA, Seeley RJ, GLP-1 and energy balance: an evidence. Nat Rev Endocrinol 2016; 12: 489.
12. Krahmer N Jr, Farese RV, Walther TC. Balancing the fat: lipid droplets and human disease. Endo Mol Med 2012; 5: 973–983.
13. Geach T: fatty pancreas linked to increased BMI and insulin resistance in children. Nat Rev Gastroenterol Hepatol 2015; 12: 489.
14. Barrera JG, Sandoval DA, D’ Alessio DA, Seeley RJ, GLP-1 and energy balance: an evidence. Nat Rev Endocrinol 2016; 12: 489.
15. Gerriets VA, Kishton RJ, Johnson MO, Cohen S, Sank P, Nichola AD et al. Foxp3 and T10-like receptor signaling balance Treg cell anabolic metabolism for suppression. Nat Immunol 2016; 17: 1459–1466.
16. Buckner JH. Mechanisms of impaired regulation by CD4<sup>+</CD4</sup> FOX P3 regulatory T cells in human autoimmune diseases. Nat Rev Immunol 2010; 10: 849–859.

17. Vasanthakumar A, Moro K, Xin A, Liao Y, Gloury R, Kawamoto S et al. The transcriptional regulators IRF4, BATF and IL-33 orchestrate development and maintenance of adipose tissue-resident regulatory T cells. Nat Immunol 2015; 16: 276–285.

18. Gao S, McMillan RP, Zhu Q, Lopaschuk GD, Huiver MW, Butler AA. Therapeutic effects of adropin on glucose tolerance and substrate utilization in diet-induced obese mice with insulin resistance. Mol Metab 2015; 4: 310–324.

19. Wong CM, Wang Y, Lee JT, Huang Z, Wu D, Xu A et al. Adropin is a brain membrane-bound protein regulating physical activity via the NBR3/Notch signaling pathway in mice. J Biol Chem 2014; 289: 25976–25986.

20. Petersen TN, Brunak S, Von HG, Nielsen H. SIGNALP 4.0: discriminating signal peptides from transmembrane regions. Nat Methods 2010; 8: 785–786.

21. Kudla G, Murray AW, Tollervey D, Plotkin JB. Coding-sequence determinants of gene expression in Escherichia coli. Science 2009; 324: 255–258.

22. Hellmann K, Kerckhofs K, Hannaert JG, Van Veldhoven P, Pipeleers D. Peroxisome proliferator-activated receptor alpha-retinoid X receptor agonists induce beta-cell protection against palmitate toxicity. Pepe J 2007; 274: 6094–6105.

23. Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M et al. PPARgamma signaling and metabolism: the good, the bad and the future. Nat Med 2013; 19: 557–566.

24. Kraus D, Yang Q, Kong D, Banks AS, Zhang L, Rodgers JT et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature 2014; 508: 258–262.

25. Knowles JW, Xie W, Zhang Z, Chenhemsetty I, Assimes T, Paanaren J et al. Identification and validation of N-acetyltransferase 2 as an insulin sensitivity gene. J Clin Invest 2015; 125: 1739–1749.

26. Zhang X, He MA, Cheng L, Zhou L, Zeng H, Wang J et al. Joint effects of antibody to heat shock protein 60, hypertension, and diabetes on risk of coronary heart disease in Chinese. Clin Chem 2008; 54: 1046–1052.

27. Gao S, Tuzar S, Mitasova R, Gao Q, Lopaschuk G, Radosiwi J, Ratnagunja C, Pillar R et al. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD (P)H oxidase and endothelial nitric oxide synthase. Circulation 2002; 105: 1656–1662.

28. Lumeng CN, Saltiel AR. Review series: Inflammatory links between obesity and metabolic disease. J Clin Invest 2011; 121: 2111–2117.

29. Mathis D. Immunological goings-on in visceral adipose tissue. Cell Metab 2013; 17: 851–859.

30. Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med 2012; 18: 363–374.

31. Tatsuzuen ME, Bunck MC, Pouwels PJ, Bontemps S, van Waesbergh JH, Schindhelm RK et al. Pancreatic fat content and beta-cell function in men with and without type 2 diabetes. Diabetes Care 2007; 31: 2916–2921.

32. Navaia S, Chathur A, Delany JP, Orlicherko LS, Baty CJ, Shiva SS et al. Lipotoxicity causes multisystem organ failure and exacerbates acute pancreatitis in obesity. Sci Trans Med 2011; 3: 707–714.